B

Braidwell Portfolio holdings

AUM $2.7B Turnover 43.12%
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+25.03%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.13B
AUM Growth
-$243M
Cap. Flow
-$918M
Cap. Flow %
-29.36%
Top 10 Hldgs %
37.92%
Holding
89
New
20
Increased
16
Reduced
29
Closed
16
Avg Time Held
1 year
Top 10 Avg Time Held
0.7 years
Top 20 Avg Time Held
0.7 years

Top Buys

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$55.4M
2
KOD icon
Kodiak Sciences
KOD
+$42.4M
3
BTSG icon
BrightSpring Health Services
BTSG
+$40.1M
4
CLDX icon
Celldex Therapeutics
CLDX
+$33.4M
5
ILMN icon
Illumina
ILMN
+$31.7M

Top Sells

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$74.8M
2
KRYS icon
Krystal Biotech
KRYS
+$67M
3
CGON icon
CG Oncology
CGON
+$58.5M
4
APGE icon
Apogee Therapeutics
APGE
+$54.4M
5
DHR icon
Danaher
DHR
+$42M

Sector Composition

Rank Sector Weight
1 Healthcare 83.49%
2 Miscellaneous 16.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RARE icon
76
Ultragenyx Pharmaceutical
RARE
$1.49B
– –
-588,700
Closed -$17.7M –
REPL icon
77
Replimune Group
REPL
$1.11B
– –
-2,750,092
Closed -$11.5M –
RNAM
78
DELISTED
Avidity Biosciences
RNAM
– –
-331,907
Closed -$14.5M –
RPRX icon
79
Royalty Pharma
RPRX
$26.2B
– –
-182,068
Closed -$6.42M –
SRPT icon
80
Sarepta Therapeutics
SRPT
$1.77B
– –
-832,100
Closed -$16M –
THC icon
81
Tenet Healthcare
THC
$21.9B
– –
-121,700
Closed -$24.7M –
VKTX icon
82
Viking Therapeutics
VKTX
$3.3B
– –
-759,455
Closed -$20M –
SION icon
83
Sionna Therapeutics
SION
$183M
– –
-314,013
Closed -$9.24M –
HTFL icon
84
Heartflow Inc
HTFL
$4.3B
– –
-50,000
Closed -$1.68M –
1 2 3
4

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q4 2025 Portfolio in Review

As of Q4 2025, Braidwell held 89 positions worth $3.13B, down 7.2% from $3.37B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Braidwell withdrew a net $918M in Q4 2025, closing 16 positions and reducing 29 holdings. Its most notable exit was Globus Medical, an estimated $28.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 73% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in Centessa Pharmaceuticals worth $54.7M.

  • Braidwell's largest Q4 2025 buy was Centessa Pharmaceuticals: 2,188,320 shares worth $54.7M.
  • Braidwell added most to Celldex Therapeutics in Q4 2025, an estimated $33.4M increase.
  • Braidwell's biggest Q4 2025 reduction was Xenon Pharmaceuticals, cutting an estimated $74.8M.
  • Braidwell fully exited Globus Medical in Q4 2025, selling an estimated $28.5M.
  • Braidwell's ten largest holdings make up 38% of its $3.13B portfolio in Q4 2025.
  • Braidwell opened 20 new positions and closed 16 in Q4 2025.
  • Braidwell's portfolio value fell 7.2% quarter-over-quarter to $3.13B.

Based on Braidwell's 13F filing for Q4 2025, filed 17 Feb 2026.